Answers to the Clinical Case

Clinical Clues Summary

• High-grade fever, productive cough, chest pain, dyspnea x 3 days
• Dull percussion note on right upper chest
• Chest X-ray: consolidation over right upper lobe
• Sputum sent for microbiology

1. Identify the Pathogen

• Right upper lobe consolidation on CXR - this is the hallmark radiographic feature of K. pneumoniae pneumonia
• Alcoholism - the single strongest risk factor for community-acquired K. pneumoniae pneumonia
• Diabetes mellitus - a major additional risk factor
• Chronic smoker (associated COPD/mucociliary damage)
• Elderly patient (reduced host immunity)

"The classic cause of community-acquired gram-negative bacillary pneumonia, K. pneumoniae (Friedlander pneumonia), causes 3-5% of CAP overall... Excessive alcohol use, diabetes, and COPD are the major risk factors for community-acquired K. pneumoniae infection." - Murray & Nadel's Textbook of Respiratory Medicine

2. Pathogenicity of Klebsiella pneumoniae

• The capsule is the most important virulence factor
• It inhibits opsonization and phagocytosis - prevents neutrophils and macrophages from engulfing the organism
• It shields pathogen-associated molecular patterns (PAMPs) required to activate Toll-like receptors (TLRs), blunting innate immune recognition
• K1 and K2 capsular types are the most common causes of serious infection
• Hypervirulent strains have increased capsule content due to altered capsule biosynthesis regulators

• An important virulence factor
• Triggers systemic inflammatory response (fever, sepsis)
• Lipid A component causes endotoxemia and septic shock

• K. pneumoniae expresses multiple siderophores that sequester iron from the host
• Iron is essential for bacterial survival and multiplication
• Yersiniabactin is expressed specifically in the lung and evades the host's lipocalin-2 neutrophil defense mechanism

• Allow adherence to respiratory epithelial cells
• Type 1 and type 3 fimbriae facilitate biofilm formation

• Massive lobar consolidation with alveolar exudate (the hallmark "brick-red currant jelly sputum" due to blood-stained mucoid sputum - though now rarely seen)
• Tissue destruction with potential cavitation and lung abscess formation
• High mortality (25-75%) if untreated, especially with bacteremia

"A major virulence factor for K. pneumoniae infection is the capsule... The capsule inhibits opsonization and phagocytosis and can shield pathogen-associated molecular patterns required to activate TLRs." - Murray & Nadel's Textbook of Respiratory Medicine

3. Interpret the Susceptibility Report

• Erythromycin - RESISTANT: Zone = 16 mm, which is ≤19 mm (resistant cutoff). This drug should NOT be used.
• Levofloxacin - SENSITIVE: Zone = 25 mm, which meets the ≥25 mm sensitive threshold exactly. This is a clinically useful drug for this patient.
• Tetracycline (1st row) - SENSITIVE: Zone = 26 mm, well above the ≥23 mm threshold.
• Chloramphenicol (1st row) - SENSITIVE: Zone = 16 mm, which is ≥15 mm - just over the sensitive threshold.
• Vancomycin (5µg) - INTERMEDIATE: Zone = 20 mm, which falls in the 17-20 mm intermediate range. Intermediate means the drug may work at higher doses or in sites of concentration, but should not be relied upon as first-line.
• Tetracycline (2nd row, likely different disk/organism) - RESISTANT: Zone = 13 mm, which is ≤13 mm (resistant).
• Chloramphenicol (20/10 disk) - SENSITIVE: Zone = 21 mm, which is ≥18 mm.
• Vancomycin (100/10 disk, likely co-trimoxazole or combination) - SENSITIVE: Zone = 25 mm, which is ≥21 mm.

Note on Vancomycin: Vancomycin is a glycopeptide active against gram-positive organisms only. Its presence on a K. pneumoniae (gram-negative) sensitivity panel is unusual - this may reflect a mixed infection or an error in the panel. K. pneumoniae is intrinsically resistant to vancomycin due to its outer membrane. The last two rows (with different disk strengths for tetracycline, chloramphenicol, and what appears labeled as vancomycin) may represent a second organism co-isolated (possibly Staphylococcus aureus given upper lobe disease in a smoker/diabetic), or the "vancomycin" label may be a mislabel for co-trimoxazole (SXT, commonly tested as 1.25/23.75 µg disk).

4. Treatment

• Gram-negative coverage including K. pneumoniae
• Lung penetration and tissue concentration
• Bioavailability (near 100% oral)

• Oxygen supplementation (maintain SpO2 >94%)
• IV fluids for hydration
• Antipyretics (paracetamol)
• If severe sepsis: blood cultures x2, early antibiotics within 1 hour
• Nutritional support

"In patients with serious infection, a two-drug regimen of a β-lactam/β-lactamase inhibitor or carbapenem with an aminoglycoside or a fluoroquinolone is recommended for treatment until susceptibility results are known." - Murray & Nadel's Textbook of Respiratory Medicine, p. 1007

Answers to the Clinical Case

Clinical Summary

• Gram-negative coccobacilli
• Non-motile
• Oxidase negative
• Does not ferment sugars (non-fermenter)
• Resistant to all antibiotics except carbapenems and colistin

1. Identify the Organism

"Acinetobacter spp are a cause of pneumonia in patients who have risk factors for antimicrobial resistant organisms, often manifested as ventilator-associated pneumonia." - Goldman-Cecil Medicine

2. What is Ventilator-Associated Pneumonia (VAP)?

Key features:

• Incidence: Occurs in up to 40% of intubated patients; it is the most frequent ICU-acquired infection and the most frequent ventilator-associated complication
• Timing: Peak incidence is 5-9 days after intubation (matching this case exactly); cumulative risk is proportional to duration of intubation
• Pathogenesis: The endotracheal tube (ETT) bypasses normal upper airway defenses (mucociliary clearance, cough reflex, IgA). Bacteria colonize the oropharynx and sub-glottic secretions accumulate above the ETT cuff, which then aspirate into the lower airways. Biofilm formation on the ETT inner surface provides a reservoir for repeated inoculation.

Diagnostic criteria:

• New or worsening infiltrate on CXR in a ventilated patient (>48h post-intubation)
• PLUS at least 2 of:
  • Fever (>38°C) or hypothermia (<36°C)
  • Leukocytosis (>12,000) or leukopenia (<4,000)
  • Purulent tracheal secretions

Microbial diagnosis:

• Non-invasive: Endotracheal aspirate (ETA) cultures + blood cultures (positive ~15% of cases)
• Invasive: Bronchoscopy with BAL (as done in this case) and protected specimen brush (PSB)

"VAP is defined as the development of pneumonia 48 or more hours after endotracheal intubation... VAP occurs in up to 40% of intubated patients; it is the most frequent ventilator-associated complication and most frequent ICU-acquired infection." - Frameworks for Internal Medicine

3. Treatment of This Patient

First-line treatment: Carbapenem

Role of Colistin (Polymyxin E):

• Since the isolate is also sensitive to colistin, inhaled colistin can be added as adjunct therapy for lung infections to achieve high local concentrations in the airways that IV colistin cannot achieve
• Colistin is preferred over polymyxin B for respiratory infections due to better lung penetration via inhalation
• Nephrotoxicity and neurotoxicity must be monitored

Combination therapy (for severe/ICU VAP):

• Carbapenem + inhaled colistin (augmented therapy)
• If available: Sulbactam-durlobactam (approved 2023 for VAP caused by A. baumannii-calcoaceticus complex; 28-day mortality 19% vs. 32% with colistin alone)

Supportive management:

• Optimize mechanical ventilation (lung-protective: Vt 6 mL/kg ideal body weight, plateau pressure <30 cm H2O)
• Daily spontaneous awakening trials (SATs) and spontaneous breathing trials (SBTs) to reduce ventilator days
• Treat underlying COPD exacerbation
• Strict infection control to prevent outbreak spread

"In susceptible strains, a carbapenem or ampicillin-sulbactam is considered first-line therapy. Some strains may only be susceptible to polymyxins (eg, polymyxin B, colistin). In such cases, inhaled colistin may be added to augment therapy." - Frameworks for Internal Medicine "Meropenem 2g q8h - carbapenem-susceptible isolates only; infuse over 3h" - Harrison's Principles of Internal Medicine, 22e (Table 167-1)

4. What is a VAP Bundle? Why is it Used?

Definition:

Why it is used:

Components of the VAP Bundle:

"Bundles of care... are evidence-based practices that are grouped together to encourage the consistent delivery of these practices... they allow for standardized care as well as decreasing variation, thereby improving healthcare quality and safety." - Current Surgical Therapy 14e

"In an effort to reduce a new bacterial infection while mechanically ventilated, the components of the VAP bundle aim to reduce bacterial colonization and prevent aspiration of contaminated secretions." - Miller's Anesthesia, 10e

Note on "YAP-bundle" in the question:

Answers to the HIV / Oral Thrush Clinical Case

Clinical Context

1. Identify the Agent + Labelled Diagrams

Microscopic Morphology of Candida albicans

• Yeast phase: small (5-7 µm), oval, thin-walled budding cells (blastoconidia)
• Hyphal/pseudohyphal phase: when invasive (seen in tissue infection)

Labelled Diagram Description (for your exam drawing):

CANDIDA ALBICANS - Microscopic Morphology

Yeast Phase (on mucosa):
    ___
   /   \     <- Blastoconidia (budding yeast, 5-7µm)
  | O  |
   \___/
     |        <- Bud (blastoconidium)
    _|_
   /   \
  |  O  |    <- Parent cell

Pseudohyphae (in tissue invasion):
  O—O—O—O—O   <- elongated, pinched at septa, NOT true hyphae
  (constrictions at junctions = hallmark of pseudohyphae)

True hyphae (parallel walls, no constriction)
  ═══════════

Chlamydospores (diagnostic for C. albicans):
     ___
  --( O )--   <- Large, thick-walled terminal/intercalary spore
     ---       <- produced on cornmeal agar

1. Germ tube test (Reynolds-Braude phenomenon): C. albicans produces germ tubes within 2-3 hours when incubated in serum at 37°C - a confirmatory and rapid test
2. Cornmeal agar: produces chlamydospores (thick-walled terminal spores) - unique to C. albicans
3. KOH mount of oral scraping: shows budding yeasts + pseudohyphae
4. Culture on Sabouraud's dextrose agar: white/cream-coloured, pasty colonies

"Morphology ranges from budding yeasts to pseudohyphae and true hyphae. Reproduction is by formation of blastoconidia (buds)." - Medical Microbiology 9e

"Diagnosis of oral thrush is generally clinical with white mucosal plaques that are removed with gentle scraping... Biopsy of affected oral tissue shows yeasts, pseudohyphae, and hyphae invading into the epithelium." - Harrison's Principles of Internal Medicine 22e

2. Risk Factors for Acquiring This Infection + CD4+ T Cell Levels

Risk Factors for Candida Infection in HIV Patients:

"Oral carriage rates are increased substantially in hospitalized patients; those with HIV infection, dentures, and diabetes; patients receiving antineoplastic chemotherapy; those receiving antibiotics." - Medical Microbiology 9e

CD4+ T Cell Levels in This Patient:

"Opportunistic infections usually do not occur in HIV-infected patients until CD4 T-cell counts have dropped from the normal level of about 1000 cells/µL to less than 200 cells/µL." - Jawetz, Melnick & Adelberg's Medical Microbiology 28e

3. Other Opportunistic Infections in This Patient

Fungi:

• Pneumocystis jirovecii pneumonia (PCP) - the most common OI; presents with dry cough, progressive dyspnea, bilateral interstitial infiltrates on CXR
• Cryptococcus neoformans - meningitis (CD4 <100); "soap bubble" lesions on brain MRI; India ink stain shows encapsulated yeast
• Histoplasma capsulatum - disseminated histoplasmosis in endemic areas
• Coccidioides immitis - disseminated coccidioidomycosis

Bacteria:

• Mycobacterium tuberculosis (TB) - reactivation TB even at higher CD4 counts
• Mycobacterium avium-intracellulare (MAC) - disseminated at CD4 <50 (fever, wasting, night sweats)
• Nocardia asteroides - pulmonary/CNS lesions
• Salmonella - recurrent bacteremia

Viruses:

• CMV (Cytomegalovirus) - retinitis (leading to blindness at CD4 <50), esophagitis, colitis
• HSV (Herpes simplex) - persistent, progressive mucocutaneous ulcers
• VZV (Varicella-zoster) - disseminated zoster
• JC polyomavirus - Progressive Multifocal Leukoencephalopathy (PML)
• EBV - oral hairy leukoplakia, B-cell lymphoma

Protozoa:

• Toxoplasma gondii - CNS toxoplasmosis (ring-enhancing lesions on CT)
• Cryptosporidium - chronic, voluminous watery diarrhea
• Isospora belli - chronic diarrhea and malabsorption

Malignancies (AIDS-defining):

• Kaposi's sarcoma (HHV-8) - skin/mucosal purple lesions
• Non-Hodgkin lymphoma (EBV-associated)
• Cervical cancer (HPV-associated, AIDS-defining in women)

"The most common opportunistic infections in untreated AIDS patients include: Protozoa (Toxoplasma, Cryptosporidium), Fungi (Candida, Cryptococcus, Histoplasma, Pneumocystis jiroveci), Bacteria (MAC, M. tuberculosis), Viruses (CMV, HSV, VZV, JC polyomavirus)." - Jawetz, Melnick & Adelberg's Medical Microbiology 28e

4. Treatment

A. Treatment of Oral Thrush (Candida albicans)

• Nystatin oral suspension (100,000 units/mL): 4-6 mL swish-and-swallow 4x/day for 7-14 days
• Clotrimazole troches (10 mg): dissolve 5x/day for 14 days - a palatable alternative to nystatin

• Fluconazole 100-200 mg orally once daily for 7-14 days - drug of choice for systemic azole therapy
• Note: fluconazole resistance is increasing, especially in patients with prior azole exposure

• Systemic fluconazole 200-400 mg/day for 14-21 days
• Alternative: itraconazole, voriconazole, or an echinocandin (caspofungin, micafungin) for refractory disease

"Mild oral thrush may be treated with topical agents such as nystatin suspension or clotrimazole troches, but moderate and severe disease or esophageal involvement should be treated with systemic, primarily azole therapy." - Harrison's Principles of Internal Medicine 22e

B. Address HIV - Optimize HAART

• Assess adherence barriers (side effects, pill burden, cost, mental health, substance use)
• Reinforce/restart antiretroviral therapy with an effective regimen (current guidelines favor integrase strand transfer inhibitor-based regimens: e.g., bictegravir/tenofovir alafenamide/emtricitabine - single-tablet once daily)
• Goal: Achieve viral suppression (HIV RNA undetectable) and CD4+ count recovery above 200 cells/µL, which will reduce recurrent OIs
• Consider OI prophylaxis if CD4+ remains <200: TMP-SMX (cotrimoxazole) for PCP prophylaxis

C. General Supportive Measures:

• Oral hygiene reinforcement
• Screen for and treat other OIs (check for PCP, TB, CMV)
• Nutritional support (oral thrush causes dysphagia and malnutrition)
• Follow-up CD4 count and HIV viral load in 4-8 weeks after HAART optimization

Answer: Mucormycosis (Rhinocerebral) in a Diabetic with DKA

Clinical Clue Analysis

1. Identify the Pathogen

"Rhizopus oryzae and R. delemar are by far the most common causes of mucormycosis in the Western Hemisphere." - Harrison's Principles of Internal Medicine 22e

2. Labelled Diagrams

A. Microscopic Morphology (KOH Wet Mount / Tissue Section)

MUCORALES - Microscopic Features (KOH Mount / Tissue)

    ←←← BROAD, RIBBON-LIKE HYPHAE (6-30 µm wide) ←←←

    ═══════════════════════════════════════════   <- True hyphae
                                                     (NO septa = ASEPTATE)
         ↑                   ↑
    Right-angle           Right-angle
    branching (90°)       branching (90°)

    Compare: Aspergillus = narrow, SEPTATE, acute-angle (45°) branching

B. Colony Morphology on SDA (Sabouraud's Dextrose Agar)

MUCORALES COLONY - SDA at 37°C

  Day 1-2: Rapid white growth spreads across the plate
  Day 3-4: Grey-white, thick, cottony-fluffy mycelium
           (fills the entire tube/plate rapidly = "lid-lifter" growth)

  Macroscopic: No pigment initially → grey-brown with age

C. Rhizopus Reproductive Structures (for exam diagram)

RHIZOPUS spp. - Key Features to Draw

      COLUMELLA (dome-shaped)
         ___
        /   \
       | Spo |  <- SPORANGIUM (round, filled with sporangiospores)
       |rng. |
        \___/
          |
          |     <- SPORANGIOPHORE (unbranched stalk)
          |
    ======|======  <- STOLON (horizontal runner)
    |            |
  [///]        [///]  <- RHIZOIDS (root-like structures at base)
                         *** PRESENT in Rhizopus (absent in Mucor)

Key distinguishing features of Rhizopus vs Mucor:
- Rhizopus: RHIZOIDS present at base of sporangiophore ✓
- Mucor: NO rhizoids ✗

"The sporangium of this mold has released its sporangiospores but remains attached to the supporting sporangiophore, and rhizoids are apparent at the base of the sporangiophore." - Jawetz, Melnick & Adelberg's Medical Microbiology

3. Clinical Diagnosis

Why this patient is uniquely susceptible:

1. Glycosylation of iron-sequestering proteins, disrupting normal iron sequestration
2. Upregulation of GRP78 (mammalian receptor) enabling Mucorales tissue penetration
3. Induction of defects in phagocytic (neutrophil and macrophage) function
4. Enhanced CotH expression - a Mucorales-specific protein that mediates host cell invasion by binding GRP78

"The acidosis causes dissociation of iron from sequestering proteins, resulting in enhanced fungal survival and virulence. The ketoacid β-hydroxybutyrate also increases expression of host and fungal receptors that result in fungal adherence and penetration into tissues." - Harrison's 22e

Clinical Progression of Rhinocerebral Mucormycosis:

1. Spores inhaled → germinate in nasal mucosa/sinuses
2. Hyphae invade blood vessel walls → angioinvasion → thrombosis → tissue necrosis (explains the dark/dusky serosanguineous discharge)
3. Spread from sinuses → orbit (proptosis, ophthalmoplegia) → brain (cranial nerve palsies, altered sensorium - as seen here)
4. Classic finding: Black eschar on nasal mucosa or palate (due to infarction)

4. Treatment

Step 1: Early Antifungal Therapy (URGENT - start before diagnosis confirmed)

• Dose: 5-10 mg/kg/day IV (lipid formulation preferred over deoxycholate AmB due to better safety profile)
• Mechanism: Binds ergosterol in fungal membrane → pore formation → cell lysis
• Do NOT delay - every day of delay doubles mortality

• Isavuconazole - effective alternative once stable; oral bioavailability allows step-down
• Posaconazole - oral step-down therapy after clinical improvement
• Note: Voriconazole has NO activity against Mucorales (and prior voriconazole use is actually a risk factor for breakthrough mucormycosis)

"Multiple studies have found that earlier initiation of polyene-based therapy improves survival of patients with mucormycosis... delaying treatment for mucormycosis with amphotericin B for 6 or more days after diagnosis is associated with a twofold increase in mortality." - Murray & Nadel's Textbook of Respiratory Medicine

Step 2: Surgical Debridement (URGENT)

• Wide surgical excision of all infected, necrotic tissue is mandatory
• Endoscopic sinus surgery + debridement of necrotic nasal/orbital tissue
• Repeat debridement often necessary
• Black eschar on palate or turbinates should be removed
• Surgery is as important as antifungals - neither alone is sufficient

Step 3: Reverse the Underlying Predisposing Condition

• Correct DKA aggressively: IV insulin, IV fluids, electrolyte replacement
• Bring blood glucose under tight control
• Treat metabolic acidosis - this removes the primary growth advantage of the fungus
• Stop any immunosuppressive medications if possible

Step 4: Adjunctive Measures

• Iron chelation: Avoid deferoxamine (serves as a xenosiderophore for Mucorales); consider deferasirox
• Hyperbaric oxygen (adjunct in some centers - improves phagocyte function in acidotic tissue)
• Nutritional support
• Multidisciplinary team: Infectious disease, ENT/surgery, ophthalmology, endocrinology

5. Prognosis

• Early diagnosis and treatment
• Localized (non-cerebral) disease
• Successful surgical debridement
• Rapid correction of DKA/hyperglycemia
• No dissemination at presentation

• Cerebral involvement (altered sensorium - as in this patient)
• Bilateral disease
• Delayed diagnosis (>6 days)
• Hematogenous dissemination
• Cavernous sinus thrombosis

"Optimizing the chances for successful treatment of mucormycosis requires four steps: (1) early initiation of therapy; (2) surgical debridement, when possible; (3) rapid reversal of underlying predisposing risk factors, if possible; and (4) proceeding to treat underlying malignancy, if present, without waiting." - Harrison's Principles of Internal Medicine 22e